Phase 4 N=306 Lansoprazole to Treat Children With Asthma
Asthma
Primary: Change in Juniper Asthma Control Score (ACS) — 1.1; 1.0 score — p=0.12
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen
Cutaneous Leishmaniasis
Primary: Sensitizing Effects of LtSTA in Leishmania Naive Adults — 8; 22; 9 participants
Phase 1 N=19 A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
Melanoma
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 6; 7; 6 Participants
N/A N=56 Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)
Conscious Sedation
Primary: Dosing Requirements — 100; 100 TOTAL DOSE OF MEPERIDINE, mg
Phase 1 N=22 A Study to Evaluate the Effect of Analgesics on a Walking Model of Knee Pain (0000-105)(COMPLETED)
Osteoarthritis
Primary: Change From Baseline in Time Weighted Average (TWA) Pain Intensity (PI) on a Numeric Rating Scale (NRS) Due to Self-paced Walks on Day 3 — -0.927; -1.54; -1.73 units on…
Phase 3 N=45 Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)
Crohn's Disease
Primary: Median Crohn's Disease Activity Index (CDAI) Change From Week 0 to Week 8 in the Increased Dose Period — 95.0 units on a scale
Phase 2 N=140 Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
Coronary Artery Disease · Angina, Unstable
Primary: Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment. — 301.0; 330.0; 354.0; 237.5 second
N/A N=252 Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care
Rheumatoid Arthritis · Psoriatic Arthritis · Ankylosing Spondylitis
Primary: Characteristics of Patients Prescribed Adalimumab: Education Level — 21; 2; 5; 34 participants
Phase 3 N=2,004 Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
Encephalitis · Japanese Encephalitis
Primary: Number of Participants Reporting Treatment Related Adverse Events Post Vaccination With Either ChimeriVax™-JE or a Placebo — 90; 365; 69; 297 Participants
Phase 3 N=820 A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX
Japanese Encephalitis
Primary: Number of Participants With Japanese Encephalitis (Homologous Virus) Seroconversion Following Either ChimeriVax™-JE or JE-Vax® Vaccination — NA; 324; 273; 343 Participants
Phase 2 N=128 Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine
Japanese Encephalitis
Primary: Number of Participants Who Seroconverted to the Respective Homologous JE Vaccine Strain, 28 Days After Completion of the Primary Immunization Schedule With One of 3…
Phase 4 N=40 Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis
Stable Plaque Psoriasis
Primary: Change in Modified Psoriasis Area Severity Index (PASI) Score — 2.6; 3 units on a scale — p=<0.001
N/A N=179 Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy Women
Health
Primary: Eyelash Length as Measured by Digital Image Analysis (DIA) — 7.33 Millimeters (mm)
Phase 2 N=2 Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
Primary Systemic Amyloidosis
Primary: Number of Participants With a Confirmed Hematologic Response — 0; 0; 0 participants
Phase 1 N=20 Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
Recurrent Respiratory Papillomatosis
Primary: The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient…